Drug Combination Details
| General Information of the Combination (ID: C24059) | |||||
|---|---|---|---|---|---|
| Name | Ursolic acid NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AGER | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
UA triggered ER stress, subsequently regulating apoptosis- and autophagy-related pathways and increasing GEM chemosensitivity in pancreatic cancer cells by inhibiting the expression of RAGE. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ICAM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | AsPC-1 | CVCL_0152 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| MDA-Panc-28 | CVCL_3917 | Pancreatic adenocarcinoma | Homo sapiens | |||
| In-vivo Model | A small incision was made in the left abdominal flank of male athymic nu/nu mice, and luciferase transfected Panc-28 cells (1*106) in 50L PBS were injected into the subcapsular region of the pancreas with a 27-gauge needle. | |||||
| Experimental
Result(s) |
Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment. | |||||
